PLGA Nanoparticles Co-delivering MDR1 and BCL2 SiRNA for Overcoming Resistance of Paclitaxel and Cisplatin in Recurrent or Advanced Ovarian Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2018 May 16

PMID 29760419

Citations 28

Authors

Chitra Risnayanti

Yeong-Su Jang

Jinju Lee

Hyung Jun Ahn

Affiliations

Soon will be listed here.

Abstract

The inherent or acquired resistance to paclitaxel and cisplatin, which are commonly used chemotherapeutic agents for ovarian cancer treatment, remains an important issue in chemotherapy of multidrug resistant ovarian cancer. Currently, it is still challenging to deal with the recurrent or advanced stage ovarian cancer. When drug efflux and anti-apoptotic pathways are highly interdependent and also involved in developing the resistance of multidrug resistant ovarian cancer, simultaneous inhibition of both pathways represents the potential targets to enhance the efficacy of chemotherapy. Here, we introduce PLGA nanoparticles system as a "dual RNAi delivery system" to contain both MDR1 and BCL2 siRNA, which is designed for simultaneous inhibition of drug efflux and cell death defense pathways. In the present studies, siRNA-loaded PLGA nanoparticles efficiently elicit the simultaneous suppression of both genes, which consequently shows more enhanced drug-sensitivity than sole suppression of drug efflux or anti-apoptosis in the resistant ovarian cancer cells, owing to the interdependence of both pathways. Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively.

Citing Articles

Anticancer Effects of MAPK6 siRNA-Loaded PLGA Nanoparticles in the Treatment of Breast Cancer.

Toruntay C, Poyraz F, Susgun S, Yucesan E, Mansuroglu B J Cell Mol Med. 2025; 29(2):e70309.

PMID: 39823246 PMC: 11740982. DOI: 10.1111/jcmm.70309.

Nanoenzymes: A Radiant Hope for the Early Diagnosis and Effective Treatment of Breast and Ovarian Cancers.

Shahid S, Khan A, Shahid W, Rehan M, Asif R, Nisar H Int J Nanomedicine. 2024; 19:5813-5835.

PMID: 38895143 PMC: 11184228. DOI: 10.2147/IJN.S460712.

Epigallocatechin Gallate Potentiates the Anticancer Effect of -siRNA-Loaded Polymeric Nanoparticles on Hepatocellular Carcinoma Cells.

Rodponthukwaji K, Pingrajai P, Jantana S, Taya S, Duangchan K, Nguyen K Nanomaterials (Basel). 2024; 14(1).

PMID: 38202502 PMC: 10780411. DOI: 10.3390/nano14010047.

Using Targeted Nano-Antibiotics to Improve Antibiotic Efficacy against Infections.

Le H, De E, Le Cerf D, Karakasyan C Antibiotics (Basel). 2023; 12(6).

PMID: 37370385 PMC: 10295755. DOI: 10.3390/antibiotics12061066.

Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma.

ElZallat M, Hassan M, Elkramani N, Aboushousha T, Abdellatif A, Helal N Heliyon. 2023; 9(4):e15288.

PMID: 37101621 PMC: 10123146. DOI: 10.1016/j.heliyon.2023.e15288.

References

Patil Y, Swaminathan S, Sadhukha T, Ma L, Panyam J . The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2009; 31(2):358-65. PMC: 2783414. DOI: 10.1016/j.biomaterials.2009.09.048. View

Cun D, Foged C, Yang M, Frokjaer S, Nielsen H . Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm. 2009; 390(1):70-5. DOI: 10.1016/j.ijpharm.2009.10.023. View

Gwak S, Kim B . Poly(lactic-co-glycolic acid) nanosphere as a vehicle for gene delivery to human cord blood-derived mesenchymal stem cells: comparison with polyethylenimine. Biotechnol Lett. 2008; 30(7):1177-82. DOI: 10.1007/s10529-008-9676-7. View

Lopes de Menezes D, Hu Y, Mayer L . Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined.... J Exp Ther Oncol. 2003; 3(2):72-82. DOI: 10.1046/j.1359-4117.2003.01075.x. View

Dean M, Rzhetsky A, Allikmets R . The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11(7):1156-66. DOI: 10.1101/gr.184901. View

Schmitt U, Abou El-Ela A, Guo L, Glavinas H, Krajcsi P, Baron J . Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm (Vienna). 2005; 113(7):787-801. DOI: 10.1007/s00702-005-0367-4. View

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

Perlstein I, Connolly J, Cui X, Song C, Li Q, Jones P . DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther. 2003; 10(17):1420-8. DOI: 10.1038/sj.gt.3302043. View

Wang F, Zhang D, Zhang Q, Chen Y, Zheng D, Hao L . Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. Biomaterials. 2011; 32(35):9444-56. DOI: 10.1016/j.biomaterials.2011.08.041. View

10.

Panyam J, Sahoo S, Prabha S, Bargar T, Labhasetwar V . Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm. 2003; 262(1-2):1-11. DOI: 10.1016/s0378-5173(03)00295-3. View

11.

Choi K, Choi S, Jeon H, Kim I, Ahn H . Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. ACS Nano. 2011; 5(11):8690-9. DOI: 10.1021/nn202597c. View

12.

Pang I, Iwasaki A . Control of antiviral immunity by pattern recognition and the microbiome. Immunol Rev. 2011; 245(1):209-26. PMC: 3659816. DOI: 10.1111/j.1600-065X.2011.01073.x. View

13.

Verreault M, Webb M, Ramsay E, Bally M . Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 2006; 6(4):505-33. DOI: 10.2174/156652306777934838. View

14.

Okada . One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 2000; 28(1):43-70. DOI: 10.1016/s0169-409x(97)00050-1. View

15.

Panyam J, Zhou W, Prabha S, Sahoo S, Labhasetwar V . Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002; 16(10):1217-26. DOI: 10.1096/fj.02-0088com. View

16.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

17.

Donmez Y, Akhmetova L, Iseri O, Demirel Kars M, Gunduz U . Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharmacol. 2010; 67(4):823-8. DOI: 10.1007/s00280-010-1385-y. View

18.

Kim S, Jeong J, Chun K, Park T . Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir. 2005; 21(19):8852-7. DOI: 10.1021/la0502084. View

19.

Zou S, Cao N, Cheng D, Zheng R, Wang J, Zhu K . Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin. Int J Nanomedicine. 2012; 7:3823-35. PMC: 3414222. DOI: 10.2147/IJN.S29328. View

20.

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View